JP2013533217A - Ｐｅｇ化ｃ−ペプチド - Google Patents

Ｐｅｇ化ｃ−ペプチド Download PDF

Info

Publication number
JP2013533217A
JP2013533217A JP2013511302A JP2013511302A JP2013533217A JP 2013533217 A JP2013533217 A JP 2013533217A JP 2013511302 A JP2013511302 A JP 2013511302A JP 2013511302 A JP2013511302 A JP 2013511302A JP 2013533217 A JP2013533217 A JP 2013533217A
Authority
JP
Japan
Prior art keywords
peptide
pegylated
insulin
patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013511302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013533217A5 (enExample
Inventor
シェリ・バラック
ジェイムズ・キャラウェイ
ミッシェル・マツォーニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cebix Inc
Original Assignee
Cebix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cebix Inc filed Critical Cebix Inc
Publication of JP2013533217A publication Critical patent/JP2013533217A/ja
Publication of JP2013533217A5 publication Critical patent/JP2013533217A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
JP2013511302A 2010-05-17 2011-05-17 Ｐｅｇ化ｃ−ペプチド Pending JP2013533217A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34529310P 2010-05-17 2010-05-17
US61/345,293 2010-05-17
US201161448402P 2011-03-02 2011-03-02
US61/448,402 2011-03-02
PCT/US2011/036858 WO2011146518A2 (en) 2010-05-17 2011-05-17 Pegylated c-peptide

Publications (2)

Publication Number Publication Date
JP2013533217A true JP2013533217A (ja) 2013-08-22
JP2013533217A5 JP2013533217A5 (enExample) 2014-07-03

Family

ID=44992295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511302A Pending JP2013533217A (ja) 2010-05-17 2011-05-17 Ｐｅｇ化ｃ−ペプチド

Country Status (9)

Country Link
US (2) US8927488B2 (enExample)
EP (1) EP2571896A4 (enExample)
JP (1) JP2013533217A (enExample)
KR (1) KR20130115086A (enExample)
CN (1) CN103119055A (enExample)
CA (1) CA2798518A1 (enExample)
MX (1) MX2012013375A (enExample)
NZ (1) NZ603399A (enExample)
WO (1) WO2011146518A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017047788A1 (ja) * 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
JP2019045165A (ja) * 2017-08-30 2019-03-22 クラシエホームプロダクツ株式会社 毛髪タンパク質の水との相互作用測定方法
KR20190038460A (ko) * 2017-09-29 2019-04-08 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
WO2020203625A1 (ja) * 2019-03-29 2020-10-08 日油株式会社 分岐型分解性ポリエチレングリコール誘導体
JP2025504072A (ja) * 2022-01-30 2025-02-06 江蘇衆紅生物工程創薬研究院有限公司 キニン又はその誘導体のポリエチレングリコール修飾体とその薬物への使用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP4450523A3 (en) * 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US8927488B2 (en) 2010-05-17 2015-01-06 Cebix, Inc. Pegylated C-peptide
EP2755675B1 (en) * 2011-09-12 2018-06-06 Amunix Operating Inc. Glucagon-like peptide-2 compositions and methods of making and using same
CN104220086A (zh) * 2011-11-17 2014-12-17 塞比克斯股份公司 Peg化的c-肽
US20130288973A1 (en) * 2011-12-14 2013-10-31 Edmund Burke Decellularized small particle tissue
US9988433B2 (en) * 2013-03-14 2018-06-05 Mosaic Biosciences, Inc. Covalent modification of biological macromolecules
WO2013116791A1 (en) 2012-02-02 2013-08-08 Mosaic Biosciences, Inc. Biomaterials for delivery of blood extracts and methods of using same
US20150087586A1 (en) * 2012-03-29 2015-03-26 Cebix, Inc. Pegylated c-peptide
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
EP3021834A1 (en) * 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
AU2014328458B2 (en) * 2013-09-24 2020-03-12 Allergan Pharmaceuticals International Limited Method of extracting protein
KR20170116109A (ko) 2015-02-09 2017-10-18 모자이크 바이오사이언스 인코포레이션 분해성 티올-엔 중합체 및 그의 제조 방법
JP6937984B2 (ja) * 2015-03-03 2021-09-22 ナンシャ・バイオロジックス・（ホンコン）・リミテッドＮａｎｓｈａ Ｂｉｏｌｏｇｉｃｓ （Ｈｏｎｇ Ｋｏｎｇ） Ｌｉｍｉｔｅｄ ペグ化ｉｌ−１１の組成物および方法
US10627415B2 (en) 2015-03-12 2020-04-21 Board Of Trustees Of Michigan State University Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease
CN108265044B (zh) * 2016-12-31 2021-05-11 江苏众红生物工程创药研究院有限公司 聚乙二醇定点修饰的精氨酸脱亚胺酶及其制备方法与应用
ES2989204T3 (es) 2017-06-16 2024-11-25 Zealand Pharma As Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
EP3449935A1 (en) * 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
US12226546B2 (en) * 2017-09-28 2025-02-18 The Regents Of The University Of California Polyion complex polypeptide hydrogels and uses thereof
HRP20240475T8 (hr) * 2017-12-01 2024-08-02 Csl Behring Llc A1at za smanjenje rizika od nastanka akutne bolesti graft versus host nakon transplantacije hematopoetskih stanica
CA3084013A1 (en) 2017-12-01 2019-06-06 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
AU2019268410B2 (en) * 2018-05-16 2025-01-02 Csl Limited Soluble complement receptor type 1 variants and uses thereof
EP3628682A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
CN113423466B (zh) * 2018-10-25 2025-04-25 国立大学法人大阪大学 软骨病症的治疗剂
MX2021005757A (es) 2018-11-15 2021-08-11 Quantum Si Inc Metodos y composiciones para la secuenciacion de proteinas.
US20220177704A1 (en) * 2019-03-27 2022-06-09 The Regents Of Theuniversity Of California Mixtures of synthetic copolypeptide hydrogels
US12390534B2 (en) 2019-03-29 2025-08-19 Nof Corporation Branched degradable polyethylene glycol binder
CN111939244B (zh) * 2019-05-14 2024-08-06 阿莫生命科学有限公司 用于预防或治疗糖尿病并发症的药物组合物
KR102456958B1 (ko) 2019-05-14 2022-10-21 강원대학교 산학협력단 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물
JP7750489B2 (ja) * 2020-04-20 2025-10-07 塩野義製薬株式会社 Ｈｍｇｂ１部分ペプチドを含有する製剤
US12090206B2 (en) 2020-04-23 2024-09-17 The Regents Of The University Of California Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels
US12065466B2 (en) * 2020-05-20 2024-08-20 Quantum-Si Incorporated Methods and compositions for protein sequencing
CN114137094A (zh) * 2020-09-03 2022-03-04 北京渼颜空间生物医药有限公司 一种聚左旋乳酸中有关物质的检测方法
US20220401525A1 (en) * 2021-06-16 2022-12-22 Biocell Technology, Llc Use of collagen compositions for increasing telomere length

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003104913A (ja) * 2001-06-04 2003-04-09 Nobex Corp ポリアルキレングリコールを含む薬物−オリゴマー結合体の混合物、その使用及びその製造方法
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
WO2005118638A1 (en) * 2004-06-01 2005-12-15 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
JP2008531482A (ja) * 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Ｃ末端がｐｅｇ化された成長ホルモン
WO2009045122A1 (en) * 2007-10-05 2009-04-09 Company Limited 'concern O3' Medicinal agent for treating and preventing diabetes complications
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033207A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1176158A (en) * 1981-08-27 1984-10-16 Ronald E. Chance Pharmaceutical formulations comprising human insulin and human c-peptide
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FR2686759B1 (fr) 1992-01-29 1994-04-22 Sgs Thomson Microelectronics Dispositif de regulation de puissance pour un haut-parleur de poste de telephone pendant une sonnerie .
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US6410511B2 (en) * 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
GB9716790D0 (en) 1997-08-07 1997-10-15 Creative Peptides Sweden Ab Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
CA2323048C (en) 1998-03-12 2006-10-10 Shearwater Polymers, Inc. Poly(ethylene glycol) derivatives with proximal reactive groups
EP1609478A1 (en) * 1999-01-14 2005-12-28 Amylin Pharmaceuticals, Inc. Exendin agonist peptide formulations
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
JP4861586B2 (ja) 1999-12-22 2012-01-25 ネクター セラピューティックス 水溶性ポリマーの立体的に妨害される誘導体
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
DE10055857A1 (de) 2000-11-10 2002-08-22 Creative Peptides Sweden Ab Dj Neue pharmazeutische Depotformulierung
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
US7265186B2 (en) 2001-01-19 2007-09-04 Nektar Therapeutics Al, Corporation Multi-arm block copolymers as drug delivery vehicles
SI1430082T1 (sl) 2001-09-07 2010-02-26 Biocon Ltd Postopki za sintetiziranje konjugatov inzulinski polipeptid-oligomer in konjugati proinzulinski polipeptid-oligomer in postopki za njihovo sintetiziranje
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
KR100948532B1 (ko) * 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
GB0218970D0 (en) 2002-08-14 2002-09-25 Creative Peptides Sweden Ab Fragments of Insulin c-peptide
AP2005003246A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
WO2005002597A1 (en) 2003-07-02 2005-01-13 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
US7744861B2 (en) 2003-09-17 2010-06-29 Nektar Therapeutics Multi-arm polymer prodrugs
GB0323979D0 (en) 2003-10-13 2003-11-19 Creative Peptides Sweden Ab Therapeutic applications for c-peptide
AU2005238490B2 (en) * 2004-04-22 2010-11-18 Tobira Therapeutics, Inc. Improved modulators of coagulation factors
US9085659B2 (en) 2004-05-03 2015-07-21 Nektar Therapeutics Polymer derivatives comprising an imide branching point
WO2005108463A2 (en) 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Branched polyethylen glycol derivates comprising an acetal or ketal branching point
WO2006097521A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
GB0511269D0 (en) 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP1926768B1 (en) 2005-07-18 2011-09-14 Nektar Therapeutics Branched functionalized polymers using branched polyol cores
GB0601950D0 (en) 2006-01-31 2006-03-15 Creative Peptides Sweden Ab Compositions and methods of treating diabetes
JP4261531B2 (ja) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ ラクトフェリン複合体及びその製造方法
EP2043692B1 (en) * 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20110182946A1 (en) 2008-03-17 2011-07-28 Board Of Regents, The University Of Texas System Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
WO2011081915A2 (en) 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US8927488B2 (en) 2010-05-17 2015-01-06 Cebix, Inc. Pegylated C-peptide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003104913A (ja) * 2001-06-04 2003-04-09 Nobex Corp ポリアルキレングリコールを含む薬物−オリゴマー結合体の混合物、その使用及びその製造方法
JP2005525302A (ja) * 2001-11-20 2005-08-25 ファルマシア・コーポレーション 化学的に修飾されたヒト成長ホルモンコンジュゲート
WO2005118638A1 (en) * 2004-06-01 2005-12-15 Creative Peptides Sweden Ab Degradation-resistant analogues of pro-insulin c-peptide
JP2008531482A (ja) * 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Ｃ末端がｐｅｇ化された成長ホルモン
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
WO2009045122A1 (en) * 2007-10-05 2009-04-09 Company Limited 'concern O3' Medicinal agent for treating and preventing diabetes complications
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
WO2010033207A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5007026147; ＰＡＳＵＴ　Ｇ: ＥＸＰＥＲＴ　ＯＰＩＮＩＯＮ　ＯＮ　ＴＨＥＲＡＰＥＵＴＩＣ　ＰＡＴＥＮＴＳ Ｖ１４　Ｎ６, 2004, Ｐ８５９-８９４, ＡＳＨＬＥＹ　ＰＵＢＬＩＣＡＴＩＯＮＳ *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11478551B2 (en) 2015-09-18 2022-10-25 University Of Miyazaki Long-acting adrenomedullin derivative
US10842879B2 (en) 2015-09-18 2020-11-24 University Of Miyazaki Long-acting adrenomedullin derivative
US12171836B2 (en) 2015-09-18 2024-12-24 University Of Miyazaki Long-acting adrenomedullin derivative
JP6991569B2 (ja) 2015-09-18 2022-02-15 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
WO2017047788A1 (ja) * 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
JPWO2017047788A1 (ja) * 2015-09-18 2018-07-05 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
JP2019045165A (ja) * 2017-08-30 2019-03-22 クラシエホームプロダクツ株式会社 毛髪タンパク質の水との相互作用測定方法
JP7058857B2 (ja) 2017-08-30 2022-04-25 クラシエホームプロダクツ株式会社 毛髪タンパク質の水との相互作用測定方法
KR102612576B1 (ko) 2017-09-29 2023-12-12 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
KR20190038460A (ko) * 2017-09-29 2019-04-08 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
JP2020164855A (ja) * 2019-03-29 2020-10-08 日油株式会社 分岐型分解性ポリエチレングリコール誘導体
WO2020203625A1 (ja) * 2019-03-29 2020-10-08 日油株式会社 分岐型分解性ポリエチレングリコール誘導体
JP7411188B2 (ja) 2019-03-29 2024-01-11 日油株式会社 分岐型分解性ポリエチレングリコール誘導体
US12497508B2 (en) 2019-03-29 2025-12-16 Nof Corporation Branched and degradable polyethylene glycol derivative
JP2025504072A (ja) * 2022-01-30 2025-02-06 江蘇衆紅生物工程創薬研究院有限公司 キニン又はその誘導体のポリエチレングリコール修飾体とその薬物への使用

Also Published As

Publication number Publication date
EP2571896A4 (en) 2014-01-08
CN103119055A (zh) 2013-05-22
WO2011146518A9 (en) 2012-04-19
EP2571896A2 (en) 2013-03-27
CA2798518A1 (en) 2011-11-24
US8691755B2 (en) 2014-04-08
MX2012013375A (es) 2013-04-11
KR20130115086A (ko) 2013-10-21
US8927488B2 (en) 2015-01-06
US20120178676A1 (en) 2012-07-12
WO2011146518A2 (en) 2011-11-24
WO2011146518A3 (en) 2012-03-08
NZ603399A (en) 2014-09-26
US20120220542A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
US8691755B2 (en) Pegylated C-peptide
US10800827B2 (en) Insulin receptor partial agonists
US20100216690A1 (en) Pegylated Single-Chain Insulin
EP2049149B1 (en) Pegylated extended insulins
CN101166545B (zh) Glp-1聚乙二醇化的化合物
US9260503B2 (en) Multi-substituted insulins
US20240025957A1 (en) Insulin Derivative
US10040839B2 (en) Insulin derivatives and the medical uses hereof
US20120071402A1 (en) Protease Stabilized, Pegylated Insulin Analogues
EP3341403B1 (en) Novel insulin derivatives and the medical uses hereof
AU2011210165B2 (en) Novel compounds and their effects on feeding behaviour
US20150087586A1 (en) Pegylated c-peptide
US8962553B2 (en) Method of treating a diabetic subject having a microvascular impairment disorder by a pegylated C-peptide
US20190010206A1 (en) Novel Insulin Derivatives and the Medical Uses Hereof
US20180244743A1 (en) Novel Insulin Derivatives and the Medical Uses Hereof
CN118574842A (zh) 酰化胰岛素
AU2011256203A1 (en) PEGylated C-peptide
IL321000A (en) Amylin analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150707

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160202